Aberrant expression of extracellular signal-regulated kinase 5 in human prostate cancer

Oncogene

Volumn 27, Issue 21, 2008, Pages 2978-2988

  McCracken, S R C ^a   Ramsay, A ^b,c   Heer, R ^a   Mathers, M E ^d   Jenkins, B L ^a   Edwards, J ^c   Robson, C N ^a   Marquez, R ^e   Cohen, P ^e   Leung, H Y ^a,b,c,f  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d ROYAL VICTORIA INFIRMARY   (United Kingdom)

^e UNIVERSITY OF DUNDEE   (United Kingdom)

^f GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

ERK5; MEK5; Prostate cancer

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE METASTASIS; CANCER GRADING; CANCER INVASION; CANCER LOCALIZATION; CANCER SIZE; CANCER SURVIVAL; CELL LINE; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN LNCAP; ENZYME SUBSTRATE; GENE CONSTRUCT; GENE OVEREXPRESSION; GENETIC TRANSFECTION; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCORING SYSTEM; SURVIVAL RATE; SURVIVAL TIME; UPREGULATION;

AGED; AGED, 80 AND OVER; CELL PROLIFERATION; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MAP KINASE KINASE 5; MIDDLE AGED; PROGNOSIS; PROSTATIC NEOPLASMS;

EID: 43449115379     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210963     Document Type: Article

References (34)

1. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC. (1999). Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol 161: 182-187.
2. Armes JE, Trute L, White D, Southey MC, Hammet F, Tesoriero A et al. (1999). Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res 59: 2011-2017.
3. Barros JC, Marshall CJ. (2005). Activation of either ERK1/2 or ERK5 MAP kinase pathways can lead to disruption of the actin cytoskeleton. J Cell Sci 118: 1663-1671.
4. Bartlett JM, Brawley D, Grigor K, Munro AF, Dunne B, Edwards J. (2005). Type I receptor tyrosine kinases are associated with hormone escape in prostate cancer. J Pathol 205: 522-529.
5. Bouras T, Southey MC, Venter DJ. (2001). Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu. Cancer Res 61: 903-907.
6. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N et al. (2000). Metastatic patterns of prostate cancer: an autopsy study of 1589 patients. Hum Pathol 31: 578-583.
7. Buschbeck M, Ullrich A. (2005). The unique C-terminal tail of the mitogen-activated protein kinase ERK5 regulates its activation and nuclear shuttling. J Biol Chem 280: 2659-2667.
8. Cameron SJ, Malik S, Akaike M, Lerner-Marmarosh N, Yan C, Lee JD et al. (2003). Regulation of epidermal growth factor-induced connexin 43 gap junction communication by big mitogen-activated protein kinase1/ERK5 but not ERK1/2 kinase activation. J Biol Chem 278: 18682-18688.
9. Carvajal-Vergara X, Tabera S, Montero JC, Esparis-Ogando A, Lopez-Perez R, Mateo G et al. (2005). Multifunctional role of Erk5 in multiple myeloma. Blood 105: 4492-4499.
10. Chiariello M, Marinissen MJ, Gutkind JS. (2000). Multiple mitogen-activated protein kinase signaling pathways connect the cot oncoprotein to the c-jun promoter and to cellular transformation. Mol Cell Biol 20: 1747-1758.
11. Dudderidge TJ, McCracken SR, Loddo M, Fanshawe TR, Kelly JD, Neal DE et al. (2007). Mitogenic growth signalling, DNA replication licensing, and survival are linked in prostate cancer. Br J Cancer 96: 1384-1393.
12. English JM, Pearson G, Baer R, Cobb MH. (1998). Identification of substrates and regulators of the mitogen-activated protein kinase ERK5 using chimeric protein kinases. J Biol Chem 273: 3854-3860.
13. English JM, Vanderbilt CA, Xu S, Marcus S, Cobb MH. (1995). Isolation of MEK5 and differential expression of alternatively spliced forms. J Biol Chem 270: 28897-28902.
14. Gnanapragasam VJ, Robinson MC, Marsh C, Robson CN, Hamdy FC, Leung HY. (2003). FGF8 isoform b expression in human prostate cancer. Br J Cancer 88: 1432-1438.
15. Hayashi M, Fearns C, Eliceiri B, Yang Y, Lee JD. (2005). Big mitogen-activated protein kinase 1/extracellular signal-regulated kinase 5 signaling pathway is essential for tumor-associated angiogenesis. Cancer Res 65: 7699-7706.
16. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A et al. (2005). Cancer statistics, 2005. CA Cancer J Clin 55: 10-30.
17. Kamakura S, Moriguchi T, Nishida E. (1999). Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus. J Biol Chem 274: 26563-26571.
18. Kasler HG, Victoria J, Duramad O, Winoto A. (2000). ERK5 is a novel type of mitogen-activated protein kinase containing a transcriptional activation domain. Mol Cell Biol 20: 8382-8389.
19. Kato Y, Kravchenko VV, Tapping RI, Han J, Ulevitch RJ, Lee JD. (1997). BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C. EMBO J 16: 7054-7066.
20. Kato Y, Tapping RI, Huang S, Watson MH, Ulevitch RJ, Lee JD. (1998). Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. Nature 395: 713-716.
21. Kondoh K, Terasawa K, Morimoto H, Nishida E. (2006). Regulation of nuclear translocation of extracellular signal-regulated kinase 5 by active nuclear import and export mechanisms. Mol Cell Biol 26: 1679-1690.
22. Mehta PB, Jenkins BL, McCarthy L, Thilak L, Robson CN, Neal DE et al. (2003). MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion. Oncogene 22: 1381-1389.
23. Mody N, Campbell DG, Morrice N, Peggie M, Cohen P. (2003). An analysis of the phosphorylation and activation of extracellular-signal-regulated protein kinase 5 (ERK5) by mitogen-activated protein kinase kinase 5 (MKK5) in vitro. Biochem J 372: 567-575.
24. Mody N, Leitch J, Armstrong C, Dixon J, Cohen P. (2001). Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway. FEBS Lett 502: 21-24.
25. Okamoto M, Lee C, Oyasu R. (1997). Autocrine effect of androgen on proliferation of an androgen responsive prostatic carcinoma cell line, LNCAP: role of interleukin-6. Endocrinology 138: 5071-5074.
26. Pages G, Guerin S, Grall D, Bonino F, Smith A, Anjuere F et al. (1999). Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice. Science 286: 1374-1377.
27. Regan CP, Li W, Boucher DM, Spatz S, Su MS, Kuida K. (2002). Erk5 null mice display multiple extraembryonic vascular and embryonic cardiovascular defects. Proc Natl Acad Sci USA 99: 9248-9253.
28. Rubin MA, Putzi M, Mucci N, Smith DC, Wojno K, Korenchuk S et al. (2000). Rapid ('warm') autopsy study for procurement of metastatic prostate cancer. Clin Cancer Res 6: 1038-1045.
29. Selcher JC, Nekrasova T, Paylor R, Landreth GE, Sweatt JD. (2001). Mice lacking the ERK1 isoform of MAP kinase are unimpaired in emotional learning. Learn Mem 8: 11-19.
30. Sohn SJ, Sarvis BK, Cado D, Winoto A. (2002). ERK5 MAPK regulates embryonic angiogenesis and acts as a hypoxia-sensitive repressor of vascular endothelial growth factor expression. J Biol Chem 277: 43344-43351.
31. Terasawa K, Okazaki K, Nishida E. (2003). Regulation of c-Fos and Fra-1 by the MEK5-ERK5 pathway. Genes Cells 8: 263-273.
32. Uzgare AR, Kaplan PJ, Greenberg NM. (2003). Differential expression and/or activation of P38MAPK, erk1/2, and jnk during the initiation and progression of prostate cancer. Prostate 55: 128-139.
33. Wang X, Merritt AJ, Seyfried J, Guo C, Papadakis ES, Finegan KG et al. (2005). Targeted deletion of mek5 causes early embryonic death and defects in the extracellular signal-regulated kinase 5/myocyte enhancer factor 2 cell survival pathway. Mol Cell Biol 25: 336-345.
34. Zhou G, Bao ZQ, Dixon JE. (1995). Components of a new human protein kinase signal transduction pathway. J Biol Chem 270: 12665-12669.